

PWYLLGOR DATBLYGU STRATEGOL A CHYFLENWI GWEITHREDOL STRATEGIC DEVELOPMENT AND OPERATIONAL DELIVERY COMMITTEE

DYDDIAD Y CYFARFOD: DATE OF MEETING:	25 August 2022				
TEITL YR ADRODDIAD: TITLE OF REPORT:	Corporate Risks Assigned to Strategic Development and Operational Delivery Committee (SDODC)				
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Andrew Carruthers, Director of Operations				
SWYDDOG ADRODD: REPORTING OFFICER:	Joanne Wilson, Board Secretary Charlotte Beare, Assistant Director of Assurance & Risk				

Pwrpas yr Adroddiad (dewiswch fel yn addas) Purpose of the Report (select as appropriate)
Er Sicrwydd/For Assurance


ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

The Strategic Development & Operational Delivery Committee (SDODC) is asked to request assurance from the lead Executive Director for the corporate risks in the attached report that these are being managed effectively.

Cefndir / Background

Effective risk management requires a 'monitoring and review' structure to be in place to ensure that risks are effectively identified and assessed, and that appropriate controls and responses are in place.



(Risk Management Process, ISO 31000)

The Board's Committees are responsible for the monitoring and scrutiny of <u>corporate level</u> risks within their remit. They are responsible for:

Seeking assurance on the management of principal risks on the Board Assurance
Framework (BAF)/Corporate Risk Register (CRR) and providing assurance to the Board
that risks are being managed effectively and report areas of significant concern, for
example, where risk appetite is exceeded, lack of action, etc.

Page 1 of 9

- Reviewing principal and operational risks over tolerance and, where appropriate, recommend the 'acceptance' of risks that cannot be brought within Hywel Dda University Health Board's (HDdUHB) risk appetite/tolerance to the Board.
- Provide annual reports to Audit and Risk Assurance Committee (ARAC) on the effectiveness of the risk management process and management of risks within its remit.
- Identity through discussions any new/emerging risks and ensure these are assessed by management.
- Signpost any risks outside of its remit to the appropriate HDdUHB Committee.
- Use risk registers to inform meeting agendas.

These risks have been identified by individual Directors via a top down and bottom up approach and are either:

- Associated with the delivery of the Health Board objectives; or
- Significant operational risks escalated that are of significant concern and require corporate oversight and management.

Each risk on the CRR has been mapped to a Board level Committee to ensure that risks on the CRR are being managed appropriately, taking into account the gaps, planned actions and agreed tolerances, and to provide assurance to the Board through their update report on the management of these risks.

The Board has delegated a proportion of its role of scrutiny of assurances to its Committees to make the most appropriate and efficient use of expertise. Therefore, Committees should also ensure that assurance reports relevant to the principal risks are received and scrutinised and an assessment made as to the level of assurance it provides, taking into account the validity and reliability i.e. source, timeliness, methodology behind its generation and its compatibility with other assurances. This will enable the Board to place greater reliance on assurances, if they are confident that they have been robustly scrutinised by one of its Committees; and provide them with greater confidence regarding the likely achievement of strategic objectives, as well as providing a sound basis for decision-making. It is the role of Committees to challenge where assurances in respect of any component are missing or inadequate. Any gaps should be escalated to the Board.

The process for risk reporting and monitoring within HDdUHB is outlined at Appendix 1.

Asesiad / Assessment

The SDODC Terms of Reference reflect the Committee's role in providing assurance to the Board that principal risks are being managed effectively by the risk owners (Executive Leads).

The Terms of Reference state the Committee's purpose is:

- 2.6 To seek assurance on the management of principal risks within the Board Assurance Framework (BAF) and Corporate Risk Register (CRR) allocated to the Committee and provide assurance to the Board that risks are being managed effectively and report any areas of significant concern e.g. where risk tolerance is exceeded, lack of timely action.
- 2.7 To recommend acceptance of risks that cannot be brought within the UHBs risk appetite/tolerance to the Board through the Committee Update Report.
- 2.8 Receive assurance through Sub-Committee Update Reports that risks relating to their areas are being effectively managed across the whole of the Health Board's activities

(including for hosted services and through partnerships and Joint Committees as appropriate).

There are 2 risks currently aligned to SDODC (out of the 16 that are currently on the CRR). These risks can be found at Appendix 2.

Changes Since Previous Report

Total Number of Risks	2
New risks	0
De-escalated/Closed/Change of	0
lead committee	
Increase in risk score ↑	0
No change in risk score →	2
Reduction in risk score ↓	0

See note 1

The 'heat map' below includes the risks currently aligned to SDODC:

HYWEL D	HYWEL DDA RISK HEAT MAP					
	LIKELIHOOD →	LIKELIHOOD →				
IMPACT↓	RARE 1	UNLIKELY 2	POSSIBLE 3	LIKELY 4	ALMOST CERTAIN 5	
CATASTROPHIC 5						
MAJOR 4			1350 (→)	1407 (→)		
MODERATE 3						
MINOR 2						
NEGLIGIBLE 1						

Note 1- No change in risk score

There have been no changes to any risk scores since they were reported at the previous meeting.

Risk Reference & Title	Executive Director	Previous Risk Score (Jun-22)	Current Risk Score	Date of Review	Update (Extracted from Datix)
Risk 1407- Risk to delivery of Annual Recovery Plan & achievement of WG Ministerial	Director of Operations	4×4=16	4×4=16	17/06/2022	This risk will be reviewed by the risk owner on their return from leave, and for reporting to September 2022 Board. The combined impact

Page 3 of 9

3/9

Priorities for	of urgent and
the reduction	emergency care
in elective	pressures (as
waiting times	reflected in Risk
waiting times	
	1027) and a
	continuing
	significant deficit in
	available staffing
	and financial
	resources
	continues to limit
	available capacity
	for elective, urgent
	and cancer
	pathway patients
	and, as a
	consequence,
	represents a risk to
	delivery of
	Ministerial
	Measures for the
	reduction in waiting
	lists / times during
	2022/23.
	Limits to staffing
	resource both in
	theatre, and post
	operatively, was a
	challenge before
	the COVID-19
	pandemic. The
	impact of
	·
	increasing unscheduled care
	pressures
	continues to limit
	capacity to be
	dedicated to
	elective and
	surgical pathways.
	An elective care
	recovery plan has
	been developed
	which seeks to
	increase outpatient
	and treatment
	capacity beyond
	levels delivered
	prior to the
	pandemic.
	However, the
· · · · · ·	

Page 4 of 9

					capacity required during the 2022/23 year to enable achievement of the Ministerial Measures exceeds that currently available. Whilst outsourcing programmes are continuing supported by 'Recovery' funding provided by WG, the additional capacity required exceeds the level currently being commissioned and reflected with the UHB's Annual Recovery Plan.
Risk 1350 - Risk of not meeting the 75% waiting times target for 2022/26 due to diagnostics capacity and delays at tertiary centre	Director of Operations	3×4=12	3×4=12	01/08/22	The impact of COVID-19 has increased the risk of being unable to meet the target. The delays are caused by diagnostic capacity issues across the health board in line with the infection control guidance that still remains in place. The main area of concern is radiology. A decrease in capacity for appointments and results reporting within radiology, due to COVID-19 related sickness, current vacancies and planned annual leave within two of the four health board sites. Patients have been offered alternative

Page 5 of 9

5/9

appointments on other sites: however some patients have not agreed to attend and have requested an appointment close to home. Cancer performance has been on a downward trajectory since quarter 3 2021/22. This was due to the increase in COVID-19 related sickness, management of COVID-19 related flows and the overall impact on diagnostic and critical care. The consequence of which resulted in short term planned and unplanned step down of activity within outpatients and planned surgery. This has led to an increase in the backlog of patients waiting in excess of 63 days. Performance is now at 54% (June 2022) just below our current prediction of 55%.

Argymhelliad / Recommendation

SDODC is asked to seek assurance that:

- All identified controls are in place and working effectively.
- All planned actions will be implemented within stated timescales and will reduce the risk further and/or mitigate the impact, if the risk materialises.
- Challenge where assurances are inadequate.

This in turn will enable SDODC to provide the necessary assurance (or otherwise) to the Board through its Update Report, that HDdUHB is managing these risks effectively.


Amcanion: (rhaid cwblhau) Objectives: (must be completed)	
Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor:	2.6 To seek assurance on the management of principal risks within the Board Assurance Framework (BAF) and Corporate Risk Register (CRR) allocated to the Committee and provide assurance to the Board that risks are being managed effectively and report any areas of significant concern e.g. where risk tolerance is exceeded, lack of timely action.
	2.7 To recommend acceptance of risks that cannot be brought within the UHBs risk appetite/tolerance to the Board through the Committee Update Report.
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	Not applicable.
Safon(au) Gofal ac lechyd: Health and Care Standard(s):	7.1 Workforce
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Objectives Annual Report	10. Not Applicable

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	Underpinning risk on the Datix Risk Module from across HDdUHB's services reviewed by risk leads/owners.
Rhestr Termau: Glossary of Terms:	Current Risk Score - Existing level of risk taking into account controls in place.
	Target Risk Score - The ultimate level of risk that is desired by the organisation when <u>planned</u> controls (or actions) have been implemented.
	Tolerable risk – this is the level of risk that the Board agreed for each domain in September 2018 – Risk Appetite Statement.

Partion / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Datblygu Strategol A Chyflenwi Gweithredol: Parties / Committees consulted prior to Strategic Development and Operational Delivery Committee: Relevant Executive Directors.

Effaith: (rhaid cwblhau)				
Impact: (must be completed)				
Ariannol / Gwerth am Arian:	No direct impacts from report however impacts of each			
Financial / Service:	risk are outlined in risk description.			
Ansawdd / Gofal Claf:	No direct impacts from report however impacts of each			
Quality / Patient Care:	risk are outlined in risk description.			
Gweithlu:	No direct impacts from report however impacts of each			
Workforce:	risk are outlined in risk description.			
Risg:	No direct impacts from report however organisations are			
Risk:	expected to have effective risk management systems in			
	place.			
Cyfreithiol:	No direct impacts from report however proactive risk			
Legal:	management including learning from incidents and events			
	contributes towards reducing/eliminating recurrence of risk			
	materialising and mitigates against any possible legal			
	claim with a financial impact.			
Enw Da:	Poor management of risks can lead to loss of stakeholder			
Reputational:	confidence. Organisations are expected to have effective			
	risk management systems in place and take steps to			
	reduce/mitigate risks.			
Gyfrinachedd:	No direct impacts			
Privacy:	, see			
Cydraddoldeb:	No direct impacts from report however impacts of each			
Equality:	risk are outlined in risk description of individual risks.			

Appendix 1 – Committee Reporting Structure



R R	isk of	Risk (for more detail see individual risk entries)	Risk Owner	Domain	ance evel	rious core	core g-22	rend	arget	sk on no
ľ					Toler	Prev Risk S	Risk S Au	1	Ta Risk S	Ris
1	407	Risk to delivery of Annual Recovery Plan & achievement of WG Ministerial Priorities for the	Carruthers, Andrew	Safety - Patient, Staff or Public	6	N/A	4×4=16	New	3×4=12	<u>3</u>
		reduction in elective waiting times						risk		
1	350	Risk of not meeting the 75% waiting times target for 2022/26 due to diagnostics capacity	Carruthers, Andrew	Quality/Complaints/Audit	8	3×4=12	3×4=12	_	3×2=6	<u>6</u>
		and delays at tertiary centre						7		

Assurance Key:

3 Lines of Defence (Assurance)					
1st Line	Business Management	Tends to be detailed assurance but lack independence			
2nd Line	Corporate Oversight	Less detailed but slightly more independent			
3rd Line	Independent Assurance	Often less detail but truly independent			

Key - Assurance Required	NB Assurance Map will tell you if	
Detailed review of	you have sufficient sources of	
Medium level review	assurance not what those sources	
Cursory or narrow s	scope of review	are telling you

Key - Control RAG rating	
LOW	Significant concerns over the adequacy/effectiveness of the controls in place in proportion to the risks
MEDIUM	Some areas of concern over the adequacy/effectiveness of the controls in place in proportion to the risks
HIGH	Controls in place assessed as adequate/effective and in proportion to the risk
INSUFFICIENT	Insufficient information at present to judge the adequacy/effectiveness of the controls

Date Risk	Jun-22
Identified:	
Strategic Objective: 5. Safe and sustainable and accessible and kind care	

Executive Director Owner:	Carruthers, Andrew	Date of Review:	Jun-22
		Date of Next Review:	Jul-22

Description: Set out in the Annual Recovery Plan and achievement of WG Minister Priorities for the reduction in elective waiting times to target levels of 2022/23. This is caused by the impact of urgent and emergency care (as reflected in risk 1027) and a continuing significant deficit in availa staffing and financial resources to support green pathways for urgent cancer pathway patients. This could lead to an impact/affect on the care provided to patients, significant clinical deterioration, delays in a poorer outcomes, increasing pressure of adverse publicity/reduction stakeholder confidence and increased scrutiny from regulators.

Risk Rating:(Li	kelihood x Impa	ct)	
Domain:	Safety - Patie Public	Safety - Patient, Staff or Public	
Inherent Risk	Score (L x I):	5×4=20	
Current Risk S	core (L x I):	4×4=16	
Target Risk Sc	ore (L x I):	3×4=12	
Tolerable Risk	:	6	
Trend:		New risk	

Rationale for CURRENT Risk Score:

Does this risk link to any Directorate (operational) risks?

The combined impact of urgent and emergency care pressures (as reflected in risk 1027) and a continuing significant deficit in available staffing and financial resources continues to limit available capacity for elective, urgent and cancer pathway patients and, as a consequence, represents a risk to delivery of Ministerial Measures for the reduction in waiting lists/times during 2022/23.

Limits to staffing resource both in theatre, and post operatively, was a challenge before the COVID pandemic. The impact of increasing unscheduled care pressures continues to limit capacity to be dedicated to elective & surgical pathways.

An elective care recovery plan has been developed which seeks to increase outpatient and treatment capacity beyond levels delivered prior to the pandemic. However, the capacity required during the 2022/23 year to enable achievement of the Ministerial Measures exceeds that currently available. Whilst outsourcing programmes are continuing supported by Recovery funding provided by WG, the additional capacity required exceeds the level currently being commissioned and reflected with the UHB's Annual Recovery Plan.

Rationale for TARGET Risk Score:

Across the UK, there is a significant challenge for health organisations in sustaining the recovery of planned care pathways as they emerge from the pandemic. The target score of 12 is based on the realistic assessment of the level of planned care work which can be achieved both internally across the UHB and via maximum utilisation of capacity available within the independent sector, should available resource levels support commissioning of activity to the level required.

Key CONTROLS Currently in Place:

(The existing controls and processes in place to manage the risk)

Comprehensive daily management systems in place to manage planned care risks on daily basis including multiple daily multi-site calls in times of escalation.

Prioritised review of patients based on an agreed risk stratification model.

Provision of dedicated elective beds on 3 sites.

The staffing position continues to be monitored on a daily basis in accordance with safe staffing principles.

Delivery plans in place supported by daily, weekly and monthly monitoring arrangements.

Escalation plans for acute and community hospitals (within limits of staffing availability).

Outpatient transformation programme in place with a continuing focus on alternatives to face to face delivery of outpatient care to enable increases in care volumes delivered.

Robust sickness absence management arrangements in place.

Comprehensive programme of outsourcing of planned care volumes in place utilising capacity available via independent sector providers

Weekly review of outsourcing volumes and further opportunities progressed jointly by Planned Care and Commissioning teams.

Planned Care Recovery Programme for 2022/23 in place.


	Gaps in CONTROL	.S		
Identified Gaps in Controls: (Where one or more of the key controls on which the organisation is relying is not effective, or we do not have evidence that the controls are working)	How and when the Gap in control be addressed Further action necessary to address the controls gaps	By Who	By When	Progress
# Limited impact to date of the wider urgent and emergency care plan in reducing capacity pressures on acute sites and the ability to protect sufficient elective pathway capacity	Revised elective care delivery plan developed for inclusion within refreshed Annual Delivery Plan to be submitted June 2022.	Jones, Keith	30/06/2022	Draft plan developed.
for elective patients. # Theatre staffing availability to support expansion of theatre capacity at required pace and level. # Timeliness of the All Wales Commissioning Framework to support rapid decision making and commissioning of independent sector activity levels when supported by non-recurrent funding released part-way through the year. # Sufficiency of Health records service capacity to support planned expansion of outpatient activity.	Opportunities to enhance dedicated elective pathway capacity across sites is dependent upon successful delivery of the transforming urgent and emergency care plan.	Jones, Keith	31/03/2023	Insufficient elective pathway capacity at Glangwili Hospital to support sufficient internal capacity for Urology & ENT surgery.
	Workforce development and recruitment plan jointly developed between Planned Care & Workforce Team	Hire, Stephanie	31/03/2023	Partial progress achieved in recruitment of theatre staffing resources. Additional recruitment planned by Q3 in 2022/23.
	Targeted review of Health Records service vacancies and recruitment plans, led by Health Records service and supported by Planned Care & Workforce teams.	Rees, Gareth	31/07/2022	19 WTE vacancies identified. Recruitment priorities subject to ecalated review.
	Modular Unit to enable enhanced day surgical provision awaiting completion at Prince Philip Hospital.	Jones, Keith	TBC	Commissioning period delayed due to engineering issues. Timescale for resolution awaited from contractor.

	ASSURANCE MAP			Control RAG Latest Papers Gaps in ASSURANCES					RANCES		
Performance Indicators	Sources of ASSURANCE	Type of Assurance (1st, 2nd, 3rd)	Required Assurance Current Level	Rating (what the assurance is telling you about your controls	urance date) ng you your		How are the Gaps in ASSURANCE will be addressed Further action necessary to address the gaps	By Who	By When	Progress	
	Activity volumes are reported daily on situation reports	1st				None					
been developed to	Daily performance data overseen by service management	1st									
measure the system performance.	Delivery Plans overseen by Acute Services Triumvirate	1st									
	Bi-monthly reports to SDODC on progress on delivery plans and outcomes (and to Board via update report)	2nd									
	IPAR Performance Report to SDODC & Board	2nd									

Date Risk	Feb-22
Identified:	
Strategic	5. Safe and sustainable and accessible and kind care
Objective:	

Executive Director Owner:	Carruthers, Andrew	Date of Review:	Aug-22
	Strategic Development and Operational Delivery Committee	Date of Next Review:	Oct-22

Risk ID:	1350	•	There is a risk of the UHB not being able to meet the 75% target for waiting times in the ministerial measures for 2022/26 for the Single Cancer Pathway (SCP). This is caused by the reduced capacity due to the impact of COVID-19 on our ability to meet the expected demand for diagnostics and treatment delays at our tertiary centre. This could lead to an impact/affect on meeting patient expectations in regard to timely access for appropriate treatment which could potentially lead to poorer outcomes and patient experience, adverse publicity/reduction in stakeholder confidence and increased scrutiny/escalation from Welsh Government.			
Does this	Does this risk link to any Directorate (operational) risks?					



Rationale for CURRENT Risk Score:

The impact of COVID-19 has increased the risk of being unable to meet the target. The delays are caused by diagnostic capacity issues across the health board in line with the infection control guidance that still remains in place. The main area of concern is Radiology. A decrease in capacity for appointments and results reporting within radiology, due to COVID-19 related sickness, current vacancies and planned annual leave within two of the four health board sites. Patients have been offered alternative appointments on other sites, however some patients have not agreed to attend and have requested an appointment close to home.

Cancer performance has been on a downward trajectory since quarter 3 2021/22. This was due to the increase in COVID related sickness, management of COVID related flows and the overall impact on diagnostic and critical care. The consequence of which resulted in short term planned and unplanned step down of activity within outpatients and planned surgery. This has led to an increase in the backlog of patients waiting in excess of 63 days. Performance is now at 54% (June 22) just below our current prediction of 55%.

Rationale for TARGET Risk Score:

The aim is to treat patients within target waiting times, which has now been confirmed as 75% non-adjusted 2022-2026.

The tolerance level will be met if plans to increase diagnostic capacity, utilising allocated recovery funding are realised. Publication of performance data by WG recommenced in Feb21 with health boards only reporting against the SCP, with no wait adjustment.

(The existing controls and processes in place to manage the risk)

A SCP Diagnostic Group with all the relevant service managers is in place to look at the capacity & demand for diagnostic services, looking at what capacity is required for a 7 day turnaround diagnostic service.
Fully established cancer tracking team in place to allow patients to be proactively tracked through their pathways.

A new cancer dashboard has now been developed by Informatics with the support of Business Intelligence (BI) SCP funding from the Wales Cancer Network. This is now live with accesses for Cancer Services staff and Service Managers. This will allow MDTs to actively monitor tumour site specific patients on a SCP.

A Rapid Diagnosis Clinic (RDC) has been launched within the health board. Currently 1 clinic per week being held in PPH.

Funding has now been secured and plans are being discussed to role this service out across all 3 counties.

As per the Wales Bowel Cancer Initiative, a successful FIT10 screening in the management of USC patients on a colorectal pathway was implemented in Jun20. This initiative is due to be rolled out to primary care by the endoscopy service by April 2023.

Digital Delivery of Care was implemented during the first wave of the pandemic, resulting in two thirds of patients receiving virtual appointments and only a third requiring face to face appointments.

Virtual appointments are being undertaken via digital solutions e.g. Attend Anywhere.

Weekly Cancer Watchtower meetings where services managers are in attendance. The function of this group is to monitor and address service demand, capacity and risk issues.

Monthly performance meetings with Welsh Government.

Trajectory performance plans are currently being developed for each tumour site by the relevant services, with regards to improving performance. This also includes Backlog Trajectory plans on how these improvements will be achieved.

	Gaps in CONTROLS					
one or more of the key controls on	How and when the Gap in control be addressed Further action necessary to address the controls gaps	By Who	By When	Progress		
diagnostic services to address required levels of activity to support SCP. Key diagnostic information systems	The Wales Cancer Network are employing Single Cancer Pathway (SCP) Project Managers for each health board across Wales to support the SCP work and the optimisation of the National Optimal Pathways	Humphrey, Lisa	31/03/2024	Project Manager appointed and took up post in Apr22. This will be a 2 year fixed term appointment to run alongside the optimisation project.		
do not support effective demand / capacity planning. Need for the implementation of new, streamlined optimal clinical pathways to reduce diagnostic demand and expedite assessment pathways. Access to green pathways and tertiary centres fluctuates depending on COVID-19.	Work with newly appointed Head of Radiology to: 1) explore outsourcing opportunities and internal solutions to increase capacity to appointments and reporting utilising non recurrent recovery money. 2) Investigating current capacity for diagnostics to ensure a 7-day turnaround as per the National Optimal Pathways.	Humphrey, Lisa	31/03/2023	Initial Meeting with Head of Radiology 09Mar22 to scope schedule of work for demand & capacity (C&D) plan for radiology and explore short term opportunities to increase capacity. A draft C&D has been carried out by the Radiology service in collaboration with the Delivery Unit. An SBAR that contains the cost of associated gaps in service provision has been developed in draft and presented to Cancer Delivery Board. Next step is to present to the Executive Team October 2022.		
	Review access to green surgical pathways across all sites to include access to green critical care.	Humphrey, Lisa	30/04/2022 30/09/2022	BGH & WGH Green elective pathway has been re-established. A plan for pre COVID theatre capacity to return for all hospital sites by end Sep 22.		
	Introduce a central point of contact for navigator as a pilot to coordinate radiology USC appointments and reporting from Mar22	Humphrey, Lisa	Completed	The Radiology Navigator took up post in April 22.		

7 of 11

Cancer Pathway Review Panel has been implemented to identify any risk for those patients who have not received their treatment within 146 days.

Process in place that improves time for patients to first outpatient appointment to improve the 28 day performance target (all patients to be informed...etc).

Deep dive pathway review for poorest performing tumour sites urology, lower GI, gynaecology.

Continue to escalate concerns regarding tertiary centre capacity and associated delays.

Each MDT to review and adopt	Humphrey,	31/03/2023	The Macmillan Cancer Quality
recommended optimal tumour site specific	Lisa	timescales	Improvement Manager is working
pathways		may change	with the teams with regards to
		depending on	implementing the new pathways.
		COVID	Due to the pandemic, the services
			have not been able to implement
			the new pathways in full, due to the
			restrictions around services and staff

	ASSURANCE MAP		
Performance Indicators	Sources of ASSURANCE	Type of Assurance	Required Assurance
		(1st, 2nd, 3rd)	Current Level
Internal targets - Looking at the performance per	Daily/weekly/monthly/ monitoring arrangements by management	1st	
tumour site individually concentrating on those tumour sites under 50% ie Gynae, Lower GI and Urology. Monitoring the 28 day performance and overall	Monitor outpatient appointments booked beyond 10 days to identify	1st	
	Service plans in response to COVID-19 overseen and agreed by Bronze Acute & Gold (when instigated)	2nd	
	IPAR Performance Report to SDODC & Board	2nd	
performance for each tumour site.	Monthly oversight by Delivery Unit, WG	3rd	

Control RAG	Latest Papers
Rating (what	(Committee &
the assurance	date)
is telling you	
about your	
controls	
	*
	Implementatio
	n of Single
	Cancer
	Pathway
	Report - BPPAC
	- Feb20
	* COVID-19
	Impact on
	Cancer Services
	- Board -
	May20
	* Cancer
	Updated to
	QSEAC Jun20 &
	OpQSESC Jul20
	* Risk 633
	QSEAC - Feb21
	& Aug21
	* IPAR Report -
	Board - Jan22

	Gaps in ASSURANCES					
in Assurance:	How are the Gaps in ASSURANCE will be addressed Further action necessary to address the gaps	By Who	By When	Progress		
None identified.						

		RISK SCORIN	IG MATRIX		
		Likelihood x Impa	act = Risk Score		
Likelihood	1	2	3	4	5
Descriptor	Rare	Unlikely	Possible	Likely	Almost Certain
Frequency - How often might it/does it happen?	This will probably never happen/recur (except in very exceptional circumstances).	Do not expect it to happen/recur but it is possible that it may do so.	It might happen or recur occasionally.	It might happen or recur occasionally.	It will undoubtedly happen/recur, possibly frequently.
(how many times will the adverse consequence being assessed actually be realised?)	Not expected to occur for years.*	Expected to occur at least annually.*	Expected to occur at least monthly.*	Expected to occur at least weekly.*	Expected to occur at least daily.*
		*	time-framed descriptors of frequen	су	
Probability - Will it happen or not? (what is the chance the adverse consequence will occur in a given reference period?)	(0-5%*)	(5-25%*)	(25-75%*)	(75-95%*)	(>95%*)
		*used to assign a probability score f	or risks related to time-limited or on	e off projects or business objective	S.
Risk Impact Domains	Negligible - 1	Minor - 2	Moderate - 3	Major - 4	Catastrophic - 5
Safety of Patients, Staff or Public	Minimal injury requiring no/minimal intervention or treatment.	Minor injury or illness, requiring minor intervention.	Moderate injury requiring professional intervention.	Major injury leading to long-term incapacity/disability.	Incident leading to death.
	No time off work.	Requiring time off work for >3 days	Requiring time off work for 4-14 days.	Requiring time off work for >14 days.	Multiple permanent injuries or irreversible health effects.
			15 days. Agency reportable incident. An event which impacts on a small	Increase in length of hospital stay by >15 days. Mismanagement of patient care with long-term effects.	An event which impacts on a large number of patients.
Quality, Complaints or Audit	Peripheral element of treatment or service suboptimal.	Overall treatment or service suboptimal.	number of patients. Treatment or service has significantly reduced effectiveness.	Non-compliance with national standards with significant risk to	Totally unacceptable level or quality of treatment/service.
Addit	Informal complaint/inquiry.	Formal complaint.	Formal complaint -	patients if unresolved. Multiple complaints/ independent	Gross failure of patient safety if findings not acted on.
		Local resolution.	Escalation.	review. Low achievement of performance/delivery requirements.	Inquest/ombudsman inquiry.
		Single failure to meet internal standards.	Repeated failure to meet internal standards.	Critical report.	Gross failure to meet national standards/performance
		Minor implications for patient safety if unresolved. Reduced performance if unresolved.	Major patient safety implications if findings are not acted on.		requirements.
Workforce & OD	Short-term low staffing level that temporarily reduces service quality	Low staffing level that reduces the service quality.	due to lack of staff.	Uncertain delivery of key objective/service due to lack of staff.	staff.
	(< 1 day).		Unsafe staffing level or competence (>1 day). Low staff morale.	Unsafe staffing level or competence (>5 days). Loss of key staff.	Ongoing unsafe staffing levels or competence. Loss of several key staff.
			Poor staff attendance for mandatory/key training.	Very low staff morale. No staff attending mandatory/ key training.	No staff attending mandatory training /key training on an ongoing basis.
Statutory Duty or Inspections	No or minimal impact or breach of guidance/ statutory duty.	Breach of statutory legislation.	Single breach in statutory duty.	Enforcement action	Multiple breaches in statutory duty.
		Reduced performance levels if unresolved.	Challenging external recommendations/improvement notice.	Multiple breaches in statutory duty. Improvement notices.	Prosecution. Complete systems change required.
				Low achievement of performance/delivery requirements.	Low achievement of performance/delivery requirements.
				Critical report.	Severely critical report.

9/11 18/20

Adverse Publicity or	Rumours.	Local media coverage – short-term	Local media coverage – long-term	National media coverage with <3	National media coverage with >3
Reputation		reduction in public confidence. Elements of public expectation not being met.	reduction in public confidence.	days service well below reasonable public expectation.	days service well below reasonable public expectation. AMs concerned (questions in the Assembly).
	Potential for public concern.	-			Total loss of public confidence.
Business Objectives or Projects	Insignificant cost increase/ schedule slippage.	<5 per cent over project budget. Schedule slippage.	5–10 per cent over project budget. Schedule slippage.	Non-compliance with national 10–25 per cent over project budget. Schedule slippage. Key objectives not met.	Incident leading >25 per cent over project budget. Schedule slippage. Key objectives not met.
Finance including Claims	Small loss.	Loss of 0.1–0.25 per cent of budget.	Loss of 0.25–0.5 per cent of budget.	Uncertain delivery of key objective/Loss of 0.5–1.0 per cent of budget.	Non-delivery of key objective/ Loss of >1 per cent of budget.
	Risk of claim remote.	Claim less than £10,000.	Claim(s) between £10,000 and £100,000.	Claim(s) between £100,000 and £1 million.	Failure to meet specification/ slippage Claim(s) >£1 million.
civice of Business	Loss/interruption of >1 hour. Minor disruption.	Loss/interruption of >8 hours.	Loss/interruption of >1 day.	Loss/interruption of >1 week.	Permanent loss of service or facility
interruption or disruption	Willion distribution	Some disruption manageable by altered operational routine.	Disruption to a number of operational areas within a location and possible flow onto other locations.	All operational areas of a location compromised. Other locations may be affected.	Total shutdown of operations.
Environmental	Minimal or no impact on the environment.	Minor impact on environment.	Moderate impact on environment.	Major impact on environment.	Catastrophic/critical impact on environment.
Health Inequalities/ Equity	Minimal or no impact on our attempts to reduce health inequalities/improve health equity	Minor impact on our attempts to reduce health inequalities or lack of clarity on the impact we are having on health equity	Moderate impact on our attempts to reduce health inequalities or lack of sufficient information that would demonstrate that we are not widening the gap. Indications that we are having no positive impact on health improvement or health equity		Validated data clearly demonstrating a disproportionate widening of health inequalities or a negative impact on health improvement and/or health equity

RISK MATRIX

	LIKELIHOOD →				
IMPACT ↓	RARE	UNLIKELY	POSSIBLE	LIKELY	ALMOST CERTAIN
IIVIPACI 🗸	1	2	3	4	5
CATASTROPHIC 5	5	10	15	20	25
MAJOR 4	4	8	12	16	20
MODERATE 3	3	6	9	12	15
MINOR 2	2	4	6	8	10
NEGLIGIBLE 1	1	2	3	4	5

10/11 19/20

RISK ASSESSMENT - FREQUENCY OF REVIEW

RISK SCORED	DEFINITION	ACTION REQUIRED (GUIDE ONLY)	MINIMUM REVIEW FREQUENCY
15-25	Extreme	Unacceptable. Immediate action must be taken to manage the risk. Control measures should be put into place which will have an effect of reducing the impact of an event or the likelihood of an event occurring. A number of control measures may be required.	This type of risk is considered extreme and should be reviewed and progress on actions updated, at least monthly.
8-12	High	Very unlikely to be acceptable. Significant resources may have to be allocated to reduce the risk. Urgent action should be taken. A number of control measures may be required.	This type of risk is considered high and should be reviewed and progress on actions updated at least bi-monthly.
4-6	Moderate	Not normally acceptable. Efforts should be made to reduce risk, providing this is not disproportionate. Establish more precisely the likelihood & harm as a basis for determining the need for improved measures.	This type of risk is considered moderate and should be reviewed and progress on actions updated at least every six months.
1-3	Low	Risks at this level may be acceptable. If not acceptable, existing controls should be monitored & reviewed. No further action or additional controls are required.	This type of risk is considered low risk and should be reviewed and progress on actions updated at least annually.

11/11 20/20